Genovis AB
GENO.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.34B
Close$
Share Statistics
| Market cap | $1.34 Billion |
|---|---|
| Enterprise Value | $1.27 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.36 |
| Beta | 1.73 |
| Outstanding Shares | 66,522,876 |
Return
| Return on Equity | 6.65% |
|---|---|
| Return on Assets | 4.79% |
| Return on Invested Capital | 5.11% |
Valuation & Multiples
| P/E Ratio | 67.67 |
|---|---|
| PEG | -91.02 |
| Price to Sales | 10.15 |
| Price to Book Ratio | 5.08 |
| Enterprise Value to Revenue | 9.33 |
| Enterprise Value to EBIT | 63.15 |
| Enterprise Value to Net Income | 61 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$35.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$34.95 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genovis AB
42 employees
CEO: Fredrik Olsson Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cyste...